Search

Displaying results 1081 - 1090 of 1279 in total
  1. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    All three mAbs bind to a distinct portion of the GP<sub>1,2</sub> glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against

  2. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653]

  3. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment of severe, treatment-refractory...

  4. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing sympt...

  5. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in Au...

  6. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  7. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxyge...

  8. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    scaffold product are applied to the burn site and, as they contain metabolically active and viable cells, provide a variety of human growth factors and cytokines as well as extracellular matrix proteins, all

  9. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.

  10. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer.